November 2024: Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting
Quality of Life (QoL) Improvements in Patients With Hereditary Angioedema (HAE); Interim Results From the Phase 1b/2 ALPHA-STAR Clinical Trial
October 2024: American College of Allergy, Asthma & Immunology Annual Scientific Meeting
Navenibart (STAR-0215) Induces Rapid Improvements of Quality of Life in HAE Patients in the ALPHA-STAR Trial
October 2024: American College of Allergy, Asthma & Immunology Annual Scientific Meeting
Quality of Life and Burden of Disease in Patients With Hereditary Angioedema and Their Caregivers
October 2024: Global Angioedema Forum
ALPHA-STAR, a Phase 1b/2 Clinical Trial of Single and Multiple Doses of Navenibart (STAR-0215) in Patients with Hereditary Angioedema: Interim Safety and Efficacy Outcomes
October 2024: Global Angioedema Forum
Rationale and Design of the ALPHA-SOLAR Clinical Trial of Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema (HAE)
September 2024: European Academy of Dermatology and Venerology
ALPHA-STAR, a Phase 1b/2 Clinical Trial of Single and Multiple Doses of STAR-0215 in Patients with Hereditary Angioedema: Initial Safety and Efficacy Outcomes
September 2024: Bradykinin Symposium
Updated Results of a Phase 1a Trial of STAR-0215 for Hereditary Angioedema
September 2024: Bradykinin Symposium
Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215 for the Treatment of Hereditary Angioedema (HAE)
June 2024: Eastern Allergy Conference
Updated Results of a Phase 1a Trial of STAR-0215 for Hereditary Angioedema
June 2024: European Academy of Allergy and Clinical Immunology
Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215 for the Treatment of Hereditary Angioedema (HAE)
